Ligand-selective interdomain conformations of estrogen receptor-alpha

Department of Medicine, University of California, San Francisco, San Francisco, California, United States
Molecular Endocrinology (Impact Factor: 4.2). 02/2007; 21(1):49-61. DOI: 10.1210/me.2006-0075
Source: PubMed

ABSTRACT Selective estrogen receptor modulators (SERMs) inhibit estrogen activation of the estrogen receptor (ER) in some tissues but activate ER in other tissues. These tissue-selective actions suggest that SERMs may be identified with tissue specificities that would improve the safety of breast cancer and hormone replacement therapies. The identification of an improved SERM would be aided by understanding the effects of each SERM on the structure and interactions of ER. To date, the inability to obtain structures of the full-length ER has limited our structural characterization of SERM action to their antiestrogenic effects on the isolated ER ligand binding domain. We studied the effects of estradiol and the clinically useful SERMs 4-hydroxytamoxifen and fulvestrant on the conformation of the full-length ERalpha dimer complex by comparing, in living human breast cancer cells, the amounts of energy transfer between fluorophores attached to different domains of ERalpha. Estradiol, 4-hydroxytamoxifen, and fulvestrant all promoted the rapid formation of ERalpha dimers with equivalent interaction kinetics. The amino- and carboxyl-terminal ERalpha domains both contain activation functions differentially affected by these ligands, but the positions of only the carboxyl termini differed upon binding with estradiol, 4-hydroxytamoxifen, or fulvestrant. The association of a specific ERalpha dimer conformation with the binding of ligands of different clinical effect will assist the identification of a SERM with optimal tissue-selective estrogenic and antiestrogenic activities. These studies also provide a roadmap for dissecting important structural and kinetic details for any protein complex from the quantitative analysis of energy transfer.

Download full-text


Available from: Fred Schaufele, Jan 22, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Our long-term goal is to correlate the undesired escape from androgen deprivation therapy with specific molecular events in Androgen Receptor signaling in order to determine the best molecular targets for prostate cancer treatment. Studies supported by this grant indicate that the failure of tumors to respond to anti-androgen therapy corresponded best with an increased nuclear transport of AR. However, an intramolecular fold and AR dimerization, both activated abnormally by heterologous hormones (estrogen and progestin) and measured by fluorescence resonance energy transfer of CFP and YFP-tagged ARs), also was linked to four different AR mutants associated with treatment-refractory prostate proliferation. High throughput methods were developed to measure AR folding, dimerization and nuclear transport. These methods will facilitate the future identification of new drugs that block AR folding, dimerization and nuclear transport and that may prove useful in treatment-refractory therapy.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Selective Estrogen Receptor Modulators (SERMs) have been developed, but the selectivity towards the subtypes (ERα or ERβ) is not well understood. Based on three-dimensional structural properties of ligand binding domains, a model that takes into account this aspect was developed via molecular interaction fields and consensus principal component analysis (GRID/CPCA).
    Letters in Drug Design &amp Discovery 03/2008; 5(3):182-192. DOI:10.2174/157018008784083947 · 0.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Forster resonance energy transfer (FRET) detection of protein interaction in living cells is commonly measured following the expression of interacting proteins genetically fused to the cyan (CFP) and yellow (YFP) derivatives of the Aequorea victoria fluorescent protein (FP). These FPs can dimerize at mM concentrations, which may introduce artifacts into the measurement of interaction between proteins that are fused with the FPs. Here, FRET analysis of the interaction between estrogen receptors (alpha isoform, ERalpha) labeled with "wild-type" CFP and YFP is compared with that of ERalpha labeled with "monomeric" A206K mutants of CFP and YFP. The intracellular equilibrium dissociation constant for the hormone-induced ERalpha-ERalpha interaction is similar for ERalpha labeled with wild-type or monomeric FPs. However, the measurement of energy transfer measured for ERalpha-ERalpha interaction in each cell is less consistent with the monomeric FPs. Thus, dimerization of the FPs does not affect the kinetics of ERalpha-ERalpha interaction but, when brought close together via ERalpha-ERalpha interaction, FP dimerization modestly improves FRET measurement.
    Journal of Biomedical Optics 05/2008; 13(3):031207. DOI:10.1117/1.2940366 · 2.75 Impact Factor